Romidepsin
- Generic Name
- Romidepsin
- Brand Names
- Istodax
- Drug Type
- Small Molecule
- Chemical Formula
- C24H36N4O6S2
- CAS Number
- 128517-07-7
- Unique Ingredient Identifier
- CX3T89XQBK
- Background
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
- Indication
用于在已接受至少1次既往全身治疗的患者中皮肤T-细胞淋巴瘤的治疗(CTCL)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma (CTCL)
- Associated Therapies
- -
Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 1
- Registration Number
- NCT02203578
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT02181218
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir
- Conditions
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Bionor Immuno AS
- Target Recruit Count
- 26
- Registration Number
- NCT02092116
- Locations
- 🇩🇰
Aarhus University Hospital, Skejby Sygehus, Aarhus N, Denmark
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 3
- Registration Number
- NCT02061449
- Locations
- 🇺🇸
NYU Cancer Institute, New York, New York, United States
Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 4
- Registration Number
- NCT01979276
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Jennifer Amengual
- Target Recruit Count
- 57
- Registration Number
- NCT01947140
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2017-12-28
- Target Recruit Count
- 9
- Registration Number
- NCT01938833
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 59
- Registration Number
- NCT01933594
- Locations
- 🇺🇸
Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States
🇺🇸University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States
🇺🇸University of Washington AIDS CRS, Seattle, Washington, United States
A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT01913119
- Locations
- 🇰🇷
Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Seodaemun-gu, Seoul, Korea, Republic of
🇰🇷National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Weiyun Ai
- Target Recruit Count
- 24
- Registration Number
- NCT01902225
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.